Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

281 trials

NCT06839976
Recruiting
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Phase 1/2 · United States · 1 site
Registry update: 24 Sept 2026
NCT06916806
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Phase 1 · Canada, China, Germany, Spain, France, United Kingdom, Hong Kong, Japan, Netherlands, United States · 35 sites
Registry update: 19 Oct 2026
NCT06713187
Recruiting
Interleukin23 in Systemic Lupus
Not applicable · Egypt · 2 sites
Registry update: 3 Dec 2024
NCT06904729
Recruiting
Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children
Phase 3 · China · 1 site
Registry update: 1 Apr 2025
NCT06934447
Recruiting
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE
Phase 1 · China · 1 site
Registry update: 25 Apr 2025
NCT06897930
Recruiting
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Phase 1/2 · Australia, Canada, United Kingdom, United States · 19 sites
Registry update: 10 Sept 2026
NCT06947460
Recruiting
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Phase 1/2 · China · 1 site
Registry update: 30 Jul 2026
NCT06917742
Recruiting
A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
Phase 1 · Australia · 3 sites
Registry update: 16 Jul 2026
NCT06920433
Recruiting
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
Early phase 1 · China · 1 site
Registry update: 1 May 2025
NCT06902844
Recruiting
Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
Not applicable · China · 1 site
Registry update: 30 Mar 2025
NCT06946485
Recruiting
Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
Early phase 1 · China · 1 site
Registry update: 29 Jun 2026
NCT06340750
Recruiting
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
Phase 1 · United States · 1 site
Registry update: 3 Jun 2025
NCT06647069
Recruiting
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
Phase 1 · Australia, Georgia, New Zealand, South Africa · 8 sites
Registry update: 21 Oct 2026
NCT07136389
Recruiting
Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus
Phase 1 · Russia · 1 site
Registry update: 22 Aug 2025
NCT07274059
Recruiting
Allogeneic UCB-derived CAR-T for SLE
Early phase 1 · China · 2 sites
Registry update: 10 Dec 2025
NCT06801119
Recruiting
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
Phase 1 · China · 1 site
Registry update: 12 Aug 2026
NCT06925542
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · Germany, Spain, United States · 17 sites
Registry update: 26 Oct 2026
NCT06826430
Recruiting
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
Phase 1 · China · 1 site
Registry update: 7 Aug 2025
NCT07902622
Recruiting
Pakistan Arthritis and Connective Tissue Disease Network - Systemic Lupus Erythematosus
Not applicable · Pakistan · 1 site
Registry update: 29 Oct 2026
NCT06822881
Recruiting
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
Phase 1 · China · 1 site
Registry update: 10 Mar 2026

Ordered by registry start date. Freshness and sponsorship never change the order.